Alert
February 14, 2022
Willingness to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians, Oct 2021 (% of respondents)
Note
Data was provided to Insider Intelligence by Cowen & Company.Methodology
Data is from the February 2022 Cowen & Company "Physician Survey on Prescription Digital Therapeutics." 200 US physicians were surveyed during September-October, 2021, spanning across four indications: type 2 diabetes, pediatric attention-deficit/hyperactivity disorder (ADHD), substance use and opioid disorder, and chronic insomnia. The five products around which the survey centered are BT-001 (Better Therapeutics), EndeavorRx (Akili Interactive), reSET and reSET-O (Pear Therapeutics), and Somryst (Pear Therapeutics). This list is not exhaustive of all PDTs, either approved or in development. Cowen & Company, LLC and/or its affiliates make a market in the stock of Better Therapeutics and Pear Therapeutics securities.Featured In
The Rise of Digital TherapeuticsNew CPT codes for digital therapies could sway wary physicians to prescribe more DTx appsBiogen, Happify Health team up to move the needle on mental health therapies for MS patientsAmericasourceBergen integrates digital therapeutics e-prescribing with EHRsSources
Alert
Chart Title
Willingness to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians, Oct 2021 (% of respondents)Publication Date
February 14, 2022
